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Die Neugier steht immer an erster Stelle eines Problems, das 
gelöst werden will. 
 
Galileo Galilei (15.02.1564 - 08.01.1642) 
Italienischer Physiker und Astronom 
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2. Introduction 
 
2.1History of transplantation 
 
2.1.1Transplantation and mythology 
 
From time immemorial transplantation of organs or tissues has exerted a strong 
fascination on humanity. 
The earliest evidence of orthotopic transplantation has been bequeathed from the 
Bronze Age where a circular disk of bone was removed from the calvarium to 
presumably relieve intracranial pressure and later replaced as an autograft. (1) 
One of the oldest reports originates from hinduistic mythology of the 12 century 
before Christ and describes the creation of Ganesha, the god of wisdom and 
remover of obstacles, by Shiva, combining an elephant head with an 
anthropomorphic body.  
In Greek mythology the Chimera was a monstrous fire-breathing creature composed 
of the parts of multiple animals consisting of a lioness body with a tail terminated in a 
snake’s head and a goat head arising on the back at the centre of the spine. Homer’s 
description in his Iliad is the earliest surviving literary reference. (2) (Fig. 1.2)  
The modern term chimerism, describing the coexistence of donor and host cells 
arose from this chimera. 
 
               
      Figure 1.1: Ganesha (3)             Figure 1.2: Bronze figure of a chimera 
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In 430 b.c. the Chinese priest and physician Pien Ch’iao was born, who was reputed 
for his excellent diagnostic skills, excellence in pulse taking and acupuncture therapy 
was the main character of the first tale describing surgical transplantation 
procedures. He exchanged two hearts of two soldiers afflicted with an unbalanced 
equilibrium of energies. To achieve acceptance of the heart he administered powerful 
herbs after the transplantation. (4) 
The two brothers and Christian physicians Saint Cosmas and Saint Damian are 
considered the patron saints of transplantation for their reported miraculous painless 
amputation of the ulcerated leg of a Christian Roman deacon and the subsequent 
transplantation of a healthy leg of a dead Ethiopian Moor. (Fig.1.2) (5) 
 
 
Figure 1.2: Saint Cosmos and Damian performing a miraculous transplantation (6) 
 
2.1.2 Advances in surgery 
 
The first more reasonable account of early transplantation dates from the second 
century BC in which the Indian surgeon Sushruta preformed autografted skin 
transplantations to perform nose reconstructions. Encouraged by these attemps the 
Italian surgeon Gasparo Tagliacozzi performed rhinoplasty using tissue flap 
autografts. However he failed in performing the same procedure with allografts and 
attributed it to the „force and power of individuality“. (7) 
The beginning of the 20th century would mark several milestones for the advances in 
succesfull transplantation techniques.  
In 1902 the Austrian surgeon Emmerich Ullmann performed the first succesfull 
kindey transplantation in dogs. The kindeys were transplanted into the neck using 
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magnesium tubes for vessel anastomosis  and the ureter was led through the skin to 
document urine production. (8) 
Alexis Carrel achieved another milestone by performing the fist successful 
transplantation of arteries and veins. In later studies, he successfully transplanted a 
dog’s kidney to its neck. Thanks to those new techniques a fundament was laid for 
later transplantations and awarded him in 1912 the Nobel Prize. (9). 
In 1933 the Ukrainian surgeon Yu Yu Voronoy performed the first human kidney 
transplantation from a deceased donor. The recipient, a young woman suffering from 
acute renal failure due to mercuric chloride poisoning in a suicide attempt survived 
for only four days. Unfortunately the transplanted organ never functioned and 
autopsy showed necrosis of the graft. Between 1933 and 1949 Voronoy performed 5 
additional transplantations. None of his attempts was successful (10). 
In 1948 the French surgeon Küss suggested, after performing several kidney 
transplantations in dogs, a heterotopic placement of the organs into the iliac fossa. 
(11). 
In 1954 Joseph E. Murray at the Peter Bent Brigham hospital in Boston was the first 
to successfully transplant a human kidney between two HLA-identical twins. In 1962 
the same team around Murray transplanted the first human cadaveric kidney. 
Unfortunately the new organ only functioned for 9 months. (12). 
 
            
Figure 1.3: First succesfull kidney transplantation (13)       Figure 1.4: Joseph E. Murray (14) 
 
Thomas E. Starzl was the first to successfully transplant a human liver in 
Denver/Colorado in 1963. Unfortunately the fist three patients died after 2-3 weeks.  
In the same year James D. Hardy performed the first successful single lung 
transplantation at the University of Missisippi. His patient, a 58-year-old man with 
carcinoma of the left main-stem bronchus died 18 days after the transplantation was 
performed due to renal failure. (15) 
In 1966 Dr. R. Lillehei at the University of Minneapolis performed the first pancreas 
transplantation.  
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On the night of 2/3 December 1967, Christian Barnard performed the world’s first 
successful human orthtotopic heart transplantation at the University of Cape Town. 
His patient, a 53-year-old man suffered from severe coronary insufficiency. Two 
weeks after surgery the patients condition began to deteriorate after initial 
postoperative recovery and developed radiographic infiltrates in the lungs. On the 
18th day post-operatively the patient died from severe pneumonia and septicaemia. 
(16) 
 
Figure 1.5: Barnard and his patient Louis Washhansky (17) 
 
Until that time only cadavers were used for transplantation (currently termed non-
heart-beating donors) and many patients died after transplantation. In 1968 a 
Harvard committee, chaired by the anaesthesiologist Beecher, introduced the 
definition of brain death, which dramatically increased the number of available 
organs. (18) 
In 1989 the first multi-organ transplantation in adults (pancreas, liver, small bowel) 
was performed by Prof. Margreiter at the University of Innsbruck (19).  
Nine years later the French surgeon Dubernard performed the first successful hand 
transplantation in Lyon. (20) 
 
2.1.3 Advances in immunosupression 
 
Since the discovery of the human circulatory system by William Harvey around 1650 
many blood transfusions where made between animals. Jean Baptiste Denise 
performed the first documented successful blood transfusion between an animal 
(lamb) and a 15-year-old boy who suffered from fever in 1667 (21). The first 
successful documented human-to-human blood transfusion was performed by the 
British obstetrician James Blundell. He transfused blood from a man to his wife to 
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replace the amount of blood she had lost during childbirth. (22) After those early 
attempts it was Karl Landsteiner who discovered the different blood groups. He was 
awarded the Noble prize in 1930 for his work. (23) 
A milestone in understanding the immune system was achieved by the French Prof. 
Dausset in 1958 with the discovery of the major histocompatibility complex (MHC). 
Those molecules are displayed on cell surfaces and are responsible for lymphocyte 
recognition and antigen presentation. It is very rare if not even impossible that two 
individuals share the same set of MHC molecules. Thanks to this discovery it 
became clear that successful long-term transplantation could only be achieved by 
inhibition of the immune system of the recipient.  
Peter Medawar a British zoologist who was awarded the Nobel Prize in 1960 for his 
work and the discovery of acquired tolerance. Medawar was performing skin grafts 
for fire victims during World War II. He transplanted skin grafts from the patients self 
(autografts) and grafts from another individual (allograft). After macroscopic and 
histological observation of the transplanted grafts he observed a good outcome after 
performing autograft transplantation and signs of rejection by infiltration of 
lymphocytes when allograft transplantation was performed. With his work he 
demonstrated that rejection was a cell mediated immunological problem rather than 
due to surgical problems. (24) 
Murray treated his 12 first allogeneic kidney transplantation recipients with total body 
irradiation and subsequent bone marrow transplantation. Only one of his patients 
became a long-term survivor. 
A real breakthrough in the era of immunosupression was achieved by Schwartz and 
Dameshek by demonstrating that 6-mercaptopuirne (6-MP) suppressed antibody 
production and prolonged skin allograft survival. After the replacement of 6-MP by it’s 
derivate Azathioprine and the combination with corticosteroids, this 
immunosuppressant regime became the standard therapy for the following 20 years. 
(25). 
In 1978 Cyclosporine (CsA) was introduced to the field of solid organ transplantation. 
Jean-Francois Borel isolated this substance from the fungus Tolypocladium inflatum 
and was able to demonstrate immunosuppressive effects in animals.  However 
severe side effects as hepatotoxicity and nephrotoxicity where observed. (26) 
In 1983 Tacrolimus was isolated in 1983 from a soil bacterium and showed similar 
characteristics as CsA. In 2000 Sirolimus (SRL) was introduced into clinical practice. 
Kahan could demonstrate that it acts early in the cell cycle (G1-phase) by inhibition 
of the regulatory kinase mammalian target of rapamycine (mTOR). SRL likely to be 
more effective when used in combination with CsA. Due to its mTOR inhibition it acts 
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strongly anti-proliferative, thereby showing anti-tumour effects, in particular in the 
formation of malignancy after transplantation. Moreover, on of the major advantages 
is the reduced nephrotoxicity as compared to CsA.  
Mycophenolate mofetil (MMF) was introduced 1997 into clinical practice. It is the 
most effective and selective inhibitor of the de novo purine synthesis and replaced 
Azathioprine in many centres.  
Nowadays in most centres a combination maintenance therapy in addition to a 
induction therapy is used. 
 
2.1.4 Present 
 
Thanks to the advances in basic research and the implementation of new surgical 
techniques solid organ transplantation can be seen as clinical routine. However 
chronic rejection, acute rejection episodes, ischemia reperfusion injury and the in 
part severe side effects of immunosuppressant drugs need to be considered.  
Moreover the goal of organ transplantation to represent a long-term treatment after 
end stage organ failure has not yet been achieved as the following graph 
demonstrates (27). 
 
 
Fig.1.7: 5 year graft survival in more than 400 transplantation centres in over 45 countries. 
(27) 
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2.2 Allograft rejection 
 
In solid organ transplantation three forms of rejections can be distinguished: 
Hyperacute, acute and chronic rejection. 
Hyperacute rejection occurs immediately, within minutes of reperfusion and is based 
on pre-existing circulating anti-donor-MHC antibodies of the recipient. Due to an 
immediate binding of those antibodies to MHC-antigens on the surface of endothelial 
cells of the grafted organ, platelets are activated as well as the complement system. 
This reaction leads to subsequent loss of the transplanted organ. In order to prevent 
a severe systemic inflammatory response the organ needs to be directly removed. 
To minimize the occurrence of this reaction, recipients on waiting lists are screened 
for the presence of circulating antibodies by performing panel reactive antibody tests 
(PRA’s). 
Acute rejection episodes are cell mediated. They occur when a mismatch between 
the MHC system between the recipient and the donor are present. The risk of acute 
rejection episodes is highest in the first three months after transplantation. Thanks to 
new immunosuppressant drugs acute rejection episodes can be treated if 
recognized. However the occurrence of acute rejection episodes are a main risk 
factor for the development of chronic rejection. Acute rejection is a cell mediated 
inflammatory response. Mostly T-cells accumulate around the vessels of the newly 
transplanted organ and leads through activation and production of inflammatory 
cytokines to necrosis of the graft. 
Chronic rejection describes the slow dysfunction of the transplanted organ. It is 
associated with progressive sclerosis of the vessels of the allograft leading to an 
unstoppable loss of the allograft. Due to this pathomechanism chronic rejection is 
now termed chronic allograft vasculopathy (CAV). The clinical presentation and the 
pathomechanism of CAV depends on the transplanted organ: 
Chronic rejection in kidney allografts is characterized by vascular neointimal 
proliferation and glomerular sclerosis. This leads to a decreased glomerular filtration 
rate, an increase in plasma creatinine levels and resulting proteinuria and arterial 
hypertension (28). 
In heart allografts chronic rejection presents itself with myocardial infarction, 
arrhythmias and sudden death due to arterio- and arteriosclerosis of the coronary 
arteries (29). 
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An serum elevation of liver enzymes and bilirubin due to obstructive cholangiopathy 
and arteriopathy with the representation of foam cells and a change and obliteration 
of the portal vein branches are typical characteristics of chronic rejection in liver 
transplants (30). 
Bronchiolitis obliterans (BOS) is the clinical term used for the occurrence of chronic 
rejection in lung allografts. It is characterized by organized inflammation centred on 
the respiratory and terminal bronchioles (31). 
 
2.3 Heme catabolism 
 
Heme is synthesized in the mitochondria and cytosol of erythroid cells (85%) and 
hepatocytes.  
In hepatocytes the synthesized heme is incorporated into the P450 cytochromes, 
which is important for detoxification. In erythroid cells all of the synthesized heme is 
used for incorporation into hemoglobin. 
Red blood cells represent the largest repository for heme in the human body. Those 
cells have an average life span of 120 days. Thus about 6g/day of heme are 
accumulated. The first step of heme catabolism is the oxygenation, in which the 
heme ring is being opened by the endoplasmatic reticulum enzyme, heme 
oxygenase.  
Three isoforms of heme oxygenase have been characterized so far. 
HO-1 is expressed at low levels, except in the spleen where HO-1 levels are 
constantly high. Under stress conditions such as radiation, exposure to H2O2, heavy 
metals, cytokines such as IL-6 or TNF-α and lipopolysaccharide (LPS) it can rapidly 
be upregulated. 
HO-2 is expressed in most cell types under homeostatic conditions.  
A third heme oxygenase (HO-3) is not catalytically active, but is thought to work in 
oxygen sensing. 
The oxidation of heme results in the formation of biliverdin, ferric iron (Fe3+) and 
carbon monoxide. This is the only known reaction of the human body where CO is 
produced. In the next step a second bridging methylene is reduced by biliverdin 
reductase resulting in the production of bilirubin (Fig. 1.8) 
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Fig. 1.8: Heme degradation resulting in the formation of free iron, CO, biliverdin and bilirubin 
 
Bilirubin formed in this reaction is not water-soluble and is bound to albumin and 
transported to the liver where it dissociates from albumin and is up taken by the 
hepatocytes. In hepatocytes bilirubin-UDP-glucuronyltransferase (bilirubin-UGT) 
adds 2 equivalents of glucuronic acid to bilirubin, which produces a more water-
soluble form. This form is now actively secreted into the bile. In the intestine bilirubin 
is acted on by bacteria to produce the final porphyrin products, urobilinogen and 
urobilin, which are found in the faeces. (Fig. 1.9) 
 
 
Fig. 1.9: Bilirubin catabolism 
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2.3.1 Inherited disorders of bilirubin catabolism: 
 
As mentioned above, biliary excretion is the main route of disposal of bilirubin. 
Decreased excretion of bilirubin leads to the well known clinical presentation of 
jaundice. There are several inherited syndromes that lead to non-haemolytic 
hyperbilirubinemia. 
 
2.3.1.1 Inherited forms of unconjugated hyperbilirubinemia 
 
Three form of inherited unconjugated hyperbilirubinemia can be distinguished into 
the mildest form, Gilberts syndrome (GS) and two more severe clinical 
presentations, Crigler-Najar Syndrome (CN-syndrome) I and II. 
GS is the most common herediditary form of hyperbilirubinaemia and can be found in 
5% of the population. The main clinical symptom is harmless jaundice caused by 
reduced activity of the enzyme glucuronyltransferase. GS is generally considered to 
be an autosomal recessive disorder. Patients suffering from GS tend to have serum 
bilirubin levels from 1-6 mg/dl. Vitek et al published the first study on coronary heart 
disease (CAD) risk and individuals suffering from GS and found a significant 
decrease in the incidence of CAD in those patients. Vitek explained this occurrence 
with the increased serum antioxidant capacity of those patients (32). 
 
In 1952 Crigler and Najar described the first seven patients suffering from severe 
non-haemolytic jaundice (33). Six of their patients died in early childhood with 
kernicterus and since this first report the lethal inherited disorder is called Crigler-
Najar (CN) syndrome. In 1969 Arias et al. could distinguish between two forms of CN 
syndrome. Patients suffering from CN-syndrome type I did not respond to 
Phenobarbital injection (enzyme induction) and had no traces of bilirubin 
glucuronides in the bile. Patients suffering from this type of CN-syndrome normally 
died in early childhood. In contrast patients suffering from CN-syndrome Type II 
responded to Phenobarbital treatment and bilirubin glucuronides could be found in 
the bile. Those patients normally survived into adulthood. The combination of less 
severe hyperbilirubinaemia and the presence of bilirubin glucuronides in the bile 
indicate that patients suffering from CN-syndrome II have some residual bilirubin 
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glucuronidating activity whereas patients suffering from CN-syndrome I lack this 
activity completely (34). 
 
2.3.1.2 Inherited forms of conjugated hyperbilirubinemia 
 
First described in 1954 by the two pathologists from Washington Dubin and Johnson, 
this inherited form of hyperbilirubinemia is characterized by conjugated 
hyperbilirubinaemia with normal liver enzymes, a deposition of pigments into the 
liver, and a unique pattern of urinary excretion of heme metabolites 
(coproporphyrins). Dubin-Johnson-syndrome (DJS) is normally following a 
autosomal recessive inheritance. The pathomechanism of DJS is a mutation in an 
apical canalicular membrane protein responsible for the excretion of conjugated 
bilirubin called the multidrug resistance protein 2 (MRCP2). Patients suffering from 
DJS are normally asymptomatic. Worsening of jaundice due to pregnancy and the 
intake of oral contraceptives is a well-known feature of this syndrome (35). 
 
Rotor syndrome represents another similar clinical presentation of conjugated 
hyperbilirubinemia. This syndrome follows an autosomal recessive inheritance with 
unknown aetiology. Patients suffering from Rotor syndrome show a non-itching 
jaundice with occasionally abdominal pain and fever. In contrast to patients suffering 
from DJS the liver pigmentation is missing (36). 
 
2.3.2 Beneficial effects of Bilirubin/Biliverdin: 
 
As mentioned above, heme oxygenase 1 (HO-1) is induced in response to cellular 
stress and is responsible for converting the prooxidant heme molecule into equimolar 
quantities of biliverdin (BV), carbon monoxide (CO), and iron. BV is then converted to 
bilirubin (BR) by the enzyme biliverdin reductase. Recent experimental groups could 
demonstrate that induction of the HO system is an important endogenous 
mechanism for cytoprotection and that the downstream products of heme 
degradation, CO, BR, and BV, may mediate these powerful beneficial effects. These 
molecules, which were once considered to be toxic metabolic waste products, have 
recently been shown to have dose-dependent vasodilatory, antioxidant, and anti-
inflammatory properties that are particularly desirable for tissue protection during 
organ transplantation. In fact, recent work has demonstrated that administration of 
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exogenous CO, BR, or BV may offer a simple, inexpensive method to substitute for 
the cytoprotective effects of HO-1 in a variety of clinically applicable models. 
 
2.3.2.1 Bilirubin can prevent from atherosclerosis 
 
One of the major risk factors for the development of atherosclerosis has been 
suggested to be the oxygenation of low-density lipoprotein molecules (LDL) by free 
radicals, particularly reactive oxygen species (ROS) (37). Those oxidatively modified 
LDL’s are than taken up by intimal macrophages leading to the formation of foam 
cells (38). 
Many research groups attempted to prevent the oxygenation of LDL with known 
antioxidants as Vitamins A,C,E and ß-carotine (a form of vitamin A) (38). 
As mentioned above, Vitek et al. could demonstrate in a clinical trial that the 
occurrence of ischemic heart disease in patients with Gilberts syndrome was 
significantly decreased if compared to patients with normal bilirubin levels. The 
authors accounted this observation to the elevated serum antioxidant capacity and 
thereby the protection of LDL oxygenation (32). 
In the following years many publications supported Viteks finding showing an inverse 
effect of high serum bilirubin levels and the occurrence of atherosclerosis (39-44).  
Based on these findings Oellinger et al. hypothesized that bilirubin had beneficial 
effects on intimal hyperplasia in a model of carotid balloon injury. In their 
experimental design he performed carotid injury in hyperbilirubinemic Gunn rats and 
showed a significant decrease in intimal hyperplasia after injury if compared to Wistar 
rats. Comparable results could be achieved by one-hour local pre-treatment with 
biliverdin in wild type Wistar rats (45). The underlying mechanism by which BV/BR 
exerts its beneficial effect could be demonstrated in an in vitro experimental setting. 
In a proliferation assay of vascular smooth muscle cells they could demonstrate that 
administration of either BV or BR led to an arrest in cell cycle leading to a stop in 
proliferation (45). 
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2.3.2.2 Bilirubin can modulate the immune system 
 
Transplantation of solid organs has become clinical routine as successful treatment 
of end stage organ failure. However, the life long immunosupression and the hereby 
caused increased morbidity due to a higher rate of infections and the occurrence of 
cancer need to be taken in account (46). In addition therapeutic strategies to prevent 
or decrease the damage caused by ischemia reperfusion injury or chronic rejection 
are missing (47). For this reason less toxic strategies improving quality of life and 
survival of transplanted recipients need to be developed.  
Sima et al. was the first to describe immunosuppressive effects of bilirubin in 1980. In 
his experiments he could demonstrate a direct effect of bilirubin on lymphocytes and 
granculocytes in vitro as well a decrease in antibody forming cells in the spleens of 
mice being immunized and treated with bilirubin (48). 
Due to findings that HO-1 induction could counteract both acute and chronic 
rejections of transplanted solid organs arose hope that similar effects could be 
achieved through exogenous administration of its downstream products biliverdin 
and bilirubin (49-51). 
Yamashita et al. could demonstrate the immunmodulating effects of biliverdin in a 
murine model of heart transplantation. His group administered BV at a dose of 
35mg/Kg once before transplantation and then daily for 13 days after transplantation 
and could achieve a significant prolonged survival of B6AF1 allografts in DBA/2 
recipients to a median survival of 20.5 days compared to 11.5 days in untreated 
mice. When the injection rate of BV was increased to three doses per day the graft 
survival could be prolonged to over 200 days. Those long-term survivors where then 
challenged with a second heart allograft from FVB “third party” mice. Those hearts 
where promptly rejected whereas second DBA/2 allografts were accepted without 
any further immunosuppressive treatment. BV treatment induced donor-specific 
tolerance through a significant decrease of immunocompetent cell infiltration into the 
graft (52). The acceptance of the heart could be explained by the suppression of 
alloreactive T-cell responses. 
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2.3.2.3 Bilirubin ameliorates ischemia reperfusion injury 
 
In recent publications it has been documented that local HO-1 over expression in the 
transplanted graft ameliorates IRI. Same protective effects were demonstrated for its 
downstream products bilirubin and biliverdin (53-55). 
The effect of bilirubin on renal IRI is so far controversially discussed in recent 
publications.  
Kirkby et al. clamped in their model of renal IRI the pedicles of both kidneys for 30 
minutes followed by a 6h reperfusion period. Bilirubin was administered intravenously 
at a dose of 1.5mg/Kg 1h before reperfusion and continuously during reperfusion 
respectively at a dose of 20mg/Kg 1h before and during ischemia (bolus 
administration). After 6h of reperfusion animals where sacrificed and tissue samples 
as well as serum samples where collected for further analyses. This experimental 
design did not show any significant protective effects of bilirubin administration on 
renal IRI. Only serum creatinine levels in the 20mg/Kg treatment group showed a 
significant decrease if compared to the vehicle control. However, neither the 
intravenous bolus nor continuous infusion of bilirubin led to a significant protection to 
the renal medulla (56). 
Protective effects of bilirubin administration to prevent the damage caused by renal 
IRI could be demonstrated in an isolated perfused rat kidney model. The kidneys 
were flushed with BR or control perfusate before 20 min of warm ischemia. 
Subsequently a 2h perfusion period was performed. BR treatment resulted in an 
improved vascular resistance, urinary output, glomerular filtration rate, tubular 
function and mitochondrial integrity (57). 
Clark et al. could demonstrate protective effects of bilirubin treatment on cardiac 
ischemia reperfusion injury. In their experimental setting hearts of male Lewis rats 
were exposed to 30 min of ischemia followed by 60 min ex-vivo reperfusion period in 
a Langendorff heart setting. Administration of bilirubin to the perfusion solution led to 
a significant increase in cardiac recovery, reduced infarct size and preserved 
mitochondrial integrity (58) 
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2.3.2.4 Bilirubin and cancer 
 
Since oxidative stress is considered to be a major contributing factor to 
carcinogenesis and bilirubin is a potent antioxidant, it has been proposed that 
bilirubin may have protective effects on the occurrence of malignancy (59,60).  
A prospective study from Belgium examined the association between serum total 
bilirubin levels and cancer mortality in a representative sample of the Belgian 
population consisting of 5460 men and 4843 women. This group could observe 
significant decreased cancer mortality in male individuals with high normal BR serum 
concentrations. This association did not reach significance in the female group (61). 
Keshavan et al. could demonstrate in vitro that the administration of unconjugated 
bilirubin to HCT15 colon adenocarcinoma cells led to a significant reduction in viable 
carcinoma cells via induction of apoptosis through activation of caspase-9 (62). 
 
2.4 Harmful effects of bilirubin 
 
2.4.1 Kernicterus: 
 
Kernicterus represents the irreversible damage of the brain, especially the basal 
ganglia, caused by unconjugated bilirubin (not bound to albumin) in newborn. This 
symptom may be due to several pathological processes.   
Rhesus incompatibility between mother and fetus can lead to severe hemolysis of 
fetal red blood cells leading to an elevated serum level of unconjugated bilirubin. 
Since the blood brain barrier of newborn is not fully developed, the unconjugated 
bilirubin can easily infiltrate the brain and interfere with normal neuronal 
development. Another cause for the occurrence of kernicterus is the above described 
syndrome of Crigler-Najar Type I.  
Depending on the level of exposure the effects of kernicterus to the newborns brain 
range from unnoticeable to severe brain damage.  
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2.5  Ischemia reperfusion injury 
 
Cardiovascular diseases that are initiated by local or systemic ischemia remain the 
main cause of death in the United States and Europe (62). 
Ischemia is a consequence of interruption of blood supply during solid organ 
transplantation. Subsequently damage to metabolically active tissue occurs as a 
consequence of hypoxia and the lack of nutrients. If blood flow is restored to the 
ischemic organ (reperfusion) a series of events occur leading to an additional cell 
injury.   
During IRI a series of interactions between the vascular endothelium and the innate 
immune system occurs leading to an inflammatory burst (63).  
Organ ischemia induces a decrease in cellular oxidative phosphorylation resulting in 
a failure to resynthezise energy rich phosphated such as ATP and 
phosphocreatinine. This again leads to the alteration of ATP dependent membrane 
ionic pump function, favouring the entry of calcium, sodium and water into the cell.  
Within the endothelium, ischemia leads to the expression of certain proinflammatory 
cytokines, while repressing other protective gene products (constitutive nitric oxyde 
synthethase, thrombomodulin).  
All those processes during ischemia lead to the increased tissue vulnerability and 
further injury during reperfusion. 
 
2.5.1 Role of reactive oxygen species during ischemia reperfusion 
injury: 
 
Reperfusion of ischemic tissue leads to an increased formation of reactive oxygen 
species (ROS) such as superoxide anions (O2-), hydroxyl radicals (OH-) and 
hydrogen peroxide (H2O2). During normal cell metabolism low levels of reactive 
oxygen species (ROS) are formed continuously and play important roles in cellular 
homeostasis, mitosis, differentiation, and signaling (64). ROS formed under 
physiological conditions are inactivated by endogenous scavenging enzymes, such 
as superoxide dismutase (SOD), catalase, and glutathione peroxidase. 
During ischemia ATP is degraded to hypoxanthine. Under physiological 
circumstances hypoxanthine is oxidized by xanthine dehydrogenase to xanthine. 
During ischemia however, hypoxanthine dehydrogenase is converted to xanthine 
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oxidase. Xanthine oxidase needs oxygene to be able to catalyze hypoxanthine to 
xanthine. For this reason an excess of hypoxanthine is built up during ischemia in the 
cell. During reperfuison, oxygen is re-introduced into the cell and the conversion of 
hypoxanthine by xanthine oxidase results in the formation of high levels of toxic ROS 
(65).  
Since the endogenous scavenging enzymes are not efficient enough to neutralize the 
formed ROS, direct damage of the cellular membranes are caused by liped 
peroxidation (66). In addition ROS increases leukocyte activation, chemotaxis and 
leukocyte endothelial adherence after IRI. 
2.5.2 Role of the complement system during ischemia reperfusion 
injury: 
 
During ischemia reperfuison the complent system is activated and the formation of 
several pro-inflammatory cytokines is increased. Most important are the 
anaphylatoxins C3a and C5a and the complement components iC3b and C5b-9. 
Due to the activation of the complement, several endothelial leukocyte adhesion 
molecules are expressed like vascular cell adhesion molecule 1 (VCAM1), 
intracellular adhesion molecule 1 (ICAM-1), E-selectin and P-selectin (67). In addition 
to increased leukocyte-endothelial interaction, the activation of the complement 
system alters vascular homeostasis by inhibiting endothelium dependent relaxation 
(67). 
 
2.5.3 Role of leukocytes during ischemia reperfusion injury: 
 
As mentioned above, during IRI molecules are expressed on the surface of 
endothelial cells to facilitate the interaction between leukocytes and endothelial cells. 
In a first step leukocytes interact with endothelial P-selectin, which interacts with the 
leukocyte counter receptor, P-selecitn glycoprotein 1. This initial binding between 
endothelial cells and leukocytes is described as “leukocyte rolling”. The followed step 
is the firm adhesion of the leukocyte to the endothelium via binding of the leukocyte 
to endothelial expressed ICAM-1. Leukocyte transmigration into the interstitial 
compartment is facilitated by expression of platelet-endothelial cell adhesion 
molecule 1 (PECAM-1). This leukocyte recruitment and the hereby-caused release of 
ROS, proteases and elastases leads to and increased microvascular permeability, 
edema, thrombosis and cell death (67). 
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Fig.2.0: Leukocyte-endothelial cell interaction during ischemia reperfusion injury (67). 
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3. Aim of the study 
 
Nowadays organ transplantation can be seen as an established therapeutic option 
for end stage organ failure. The transplantation procedure consists out of cold 
preservation and warm revascularization resulting in ischemia reperfusion injury 
which severity affects the outcome of transplantation. 
The severity of I/R injury can be seen as a prognostic factor regarding primary non-
function of the transplanted graft and the development of chronic graft failure leading 
to late graft loss.  
The main pathomechanism of I/R injury consists of oxidative stress during cold 
preservation and an excess formation of reactive oxygen species (ROS) during 
reperfusion. 
 
Aim of this study was to test the potent antioxidant bilirubin in a kidney ischemia 
reperfusion model of the rat and to examine its effects on IRI. For this purpose we 
treated rats receiving kidney allografts after 18h of cold ischemia with bilirubin-dt/ 
biliverdin/dt in doses assigned previously in an ischemia reperfusion clamp model of 
the rat. To evaluate the potential protective effects of bilirubin on IRI serum creatinine 
levels and estimated glomerular filtration rate were assigned.  
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4. Material and Methods 
 
4.1 Reagents 
 
Bilirubin                      Frontier Scientifc  
Bilirubin-ditaurate                    Frontier Scientifc  
NaCl 0,15 M                     Fluka  
PBS                        Invitrogen  
 
4.2 Animal surgery equipment 
 
Bipolar diathermia                    Martin  
Heparin                       Heparin Immuno®  
Ketasol                       Graeub  
Liquid Nitrogen             Linde  
Operating microscope           Zeiss  
Ringer’s lactate solution          Braun AG  
Saline solution (NaCl 0.9%)          Fresenius  
Standard microsurgical instruments        S&T AG  
Suture material              Ethicon / USS DA  
Xylasol               Graeub 
Chemical analyzer Cobas Plus     Roche 
Metobolic cage        Harvard Apparatus 
Isoflurane          Benson Medical 
 
4.3 Animal housing: 
 
Animals were housed in single rat cages with free access to water and food during 
the conduction of the experiments according to regulation of the Institutional Animal 
Care and Use Committee. 
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4.4 Anesthesia: 
 
Rats were anesthetized using a isoflurane vaporizer.  
4.5 Kidney clamp model in the rat 
 
Male Lewis rats were anesthetized (80 mg/kg, i.p. pentobarbital) and prepared for 
surgery in a sterile surgical field. A long abdominal incision is made from the xyphoid 
to the symphysis pubis.  The bowel is covered with moist gauze and retracted to the 
left. The right kidney is being explanted after ligation of the ureter and the renal artery 
and vein. The left renal artery is exposed and dissected so that a vascular clamp can 
be easily applied. 
 
4.6 Orthotopic kidney transplantation in the rat 
 
4.5.1 Donor Operation 
 
Each animal was anesthetized (80 mg/kg, i.p. pentobarbital) and prepared for 
surgery in a sterile surgical field. A long abdominal incision is made from the xyphoid 
to the symphysis pubis.  The bowel is covered with moist gauze and retracted to the 
right. The right ureter is ligated at its entrance to the bladder and transected. The left 
ureter is mobilized from its surrounding tissue and the bladder is ligated at its button. 
The left kidney is completely mobilized from its retroperitoneal attachments.  1% 
xylocaine is applied around the renal pedicle to avoid vasospasms.  The infrarenal 
inferior vena cava and the aorta are mobilized and tied proximally above the renal 
pedicle and distally just proximal to the bifurcation.  A 25-guage needle is inserted 
into the infrarenal aorta, and the left kidney is perfused with approximately 3mls of 
cold heparinized, isotonic saline and subsequently with UW solution.  The perfusion 
of the left kidney will cause the organ to become pale. The solution should become 
clear once all circulating blood has been removed. After perfusion the kidney with the 
complete bladder is removed and the organ is placed in UW solution at 4°C for 18h 
of cold ischemia until transplantation is performed.  
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4.6.2 Recipient operation 
 
 Each animal will be anesthetized (80 mg/kg, i.p. pentobarbital) and prepared for 
surgery in a sterile surgical field. Body temperature will be kept constant at 37°C 
during the whole operation using an electric heating pad. A long abdominal incision is 
made and the bowel is again covered and retracted to the right. The left abdominal 
wall is retracted to the left with a small hook. The left ureter is identified and 
transected. The renal pedicel of the left recipient kidney is mobilized, tied, and 
transected, and the left recipient kidney is completely removed. After mobilization 
and ligation of the lumbar branches, the aorta and inferior vena cava (IVC) are cross-
clamped infrarenal and close to the bifurcation, respectively. The arterial 
reconstruction is performed by end-to-side anastomosis between the aortic stump of 
the donor and recipient aorta, using a 10-0 uninterrupted nylon suture, as the venous 
reconstruction is done by end to-side anastomosis between the recipient renal vein 
and the IVC of the donor. After completion of the vascular anastomosis, the distal 
and proximal vascular clamps are removed. Bladder anastomosis is performed using 
the bladder patch of the donor bladder and the recipient bladder using 7-0 Vicryl 
uninterrupted suture. After nephrectomy of the contralateral kidney, the bowel is 
replaced in its original position. The abdomen is irrigated to remove any debris and 
closed in two layers (inner layer absorbable: outer layer non-absorbable), using 4-0 
sutures. To rehydrate the animals, 3ml of Saline is injected i.v. and 7ml of Saline is 
given s.c. Postoperatively, animals are placed on a heating pad while they recovered 
from the anesthesia and have free access to food immediately after transplantation.  
For the collection of urine and calculation of the estimated glomerular filtration rate 
(eGFR) rats are palced in metabolic cages for 24h. After 24h of reperfusion animals 
are sacrificed under isoflurane anaesthesia and blood samples as well as tissue 
samples of the transplanted kidney are harvested and snap frozen for further 
analyzes. 
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Fig.2.0: Preparation and clamping of the inferior vena cava and the aorta (left image). Venal 
anastomosis between the inferior vena cava of the recipient and the renal vein of the donor 
(right image). 
 
      
Fig.2.1: Arterial anastomosis end-to-side between the recipient aorta and the donor aorta 
(left image). Result after 5 minutes of reperfusion (right image). 
 
4.7 Treatment 
 
Before kidney transplantation was performed a series of kidney ischemia reperfusion 
studies was accomplished to ascertain the right warm ischemic time and the right 
dosing regimen of bilirubin/bilirubin-ditaurate (bilirubin-dt) respectively biliverdin.  
In the clamping model a treatment regimen of 2 doses of biliverdin given 
intravenously at a dose of 17.5 mg/Kg before clamping and directly after reperfusion 
showed to be the most effective. 
For the kidney transplantation model rats where treated with 3 doses of 10mg/Kg 
bilirubin-dt applied intravenously 1h before, 15min before and 10min after 
reperfusion. (Fig. 2.2) After 24 h of reperfusion rats where sacrificed and tissue 
samples as well as blood samples where taken for further analyzes. 
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Fig.2.2: Experimental set-up for the kidney transplantation model 
 
4.8 Haematoxylin‐Eosin Staining 
 
Haematoxylin-eosin staining was performed using the following protocol: 
Slides were taken out of the freezer and air dried to remove moisture. Subsequently 
the slides were placed into a conical tube containing 0,1% Mayers-Haemotoxylin for 
10 minutes. 
In a Copling jar slides were washed with cool running ddH20 for 5 minutes. 
slides were placed into a clonical tube containing 0,5% eosin for 5 minutes. 
Slides were dipped in distilled H2O until the eosin stops streaking. To dehydrate the 
slides they were placed into 50% ethanol for 10 minutes, then in 70% ethanol for 
another 10 minutes. Specimens were equilibrated in 95% ethanol for 1 minute and in  
100 % ethanol for another 30 seconds.  
In a last step, slides were dipped in xylene for several times. A drop of Permount 
(xylene based) was placed on the slides using a glass rod and a coverslip was 
mounted.  
 
4.9 Statistical analyzes 
 
Statistical analyses were performed using Student's t-test and the data are displayed 
with prism version 4 for Mac. p<0,05 was defined as significant and p<0,01 as highly 
significant. All data are presented as mean values ± standard deviation. The relative 
densities of protein bands were analyzed by measuring optical density using the 
Image J® software.  
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4.10 Experimental groups 
 
Group I: Clamping of the left renal pedicle (artery and vein) for 30 min. (n=8) 
Group II: Clamping of the left renal pedicle for 45 min. (n=8) 
Group III: Clamping of the right renal artery for 45 min. (n=8) 
Group IV: Clamping of the right renal artery for 60 min. (n=8) 
Group V: Clamping of the right renal artery for 45min and treatment with a total of 3 
doses of biliverdin at a dose of 3mg/Kg given i.v. (n=8) 
Group VI: Clamping of the right renal artery for 45min and treatment with a total of 3 
doses of biliverdin at a dose of 10mg/Kg given i.v. (n=8) 
Group VII: Clamping of the right renal artery for 45min and treatment with a total of 2 
doses of biliverdin at a dose of 17.5mg/Kg given i.v. (n=8) 
Group VIII: Kidney transplantation after 18h of cold ischemia (n=8) 
Group IX: Kidney transplantation after 18h of cold ischemia and treatment with 3 
doses of bilirubin-dt at a dose of 10mg/Kg given i.v. (n=8) 
Group X: Kidney transplantation after 18h of cold ischemia and treatment with 3 
doses of bilirubin-dt at a dose of 3mg/Kg given i.v. (n=8) 
Group XI: Kidney transplantation after 18h of cold ischemia and treatment with 3 
doses of bilirubin-dt at a dose of 30mg/Kg given i.v. (n=8) 
Group XII: Kidney transplantation after 18h of cold ischemia and treatment with a 
bilirubin-dt flush at a dose of 125 µM. (n=3) 
Group XIII: Kidney transplantation after 18h of cold ischemia and treatment with 3 
doses of bilverdin-dt at a dose of 10mg/Kg given i.v. (n=3) 
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5. Results 
 
5.1 Clamping of the renal pedicle and its effect on serum creatinine levels 
 
The first experiments we conducted were used to find the perfect model in which a 
series of dose studies could be performed. For this purpose renal pedicles 
respectively renal arteries where clamped for different times and serum creatine 
levels where controlled at different time points. 
Clamping of the renal pedicle led to a significant increase in serum creatinine levels 
after 30 minutes respectively 45 minutes of warm ischemia. In rats where warm 
ischemic time was calculated with 30 minutes renal function recovered after 72h 
compared to those where clamping was performed for 45 minutes. (Fig 4.1) 
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Fig. 4.1: Serum creatinine levels of rats (n=8) in which the left renal pedicle (artery and vein) 
has been clamped for 30 and 45 minutes respectively. The right kidney has been removed 
before clamping. In the 30 minutes group, standard deviations were high with some rats 
showing no increase of creatinine at all. In the 45 minutes group kidneys did not recover from 
ischemia reperfusion injury until day 3, when animals were sacrificed. 
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5.2 Clamping of the renal artery alone vs. clamping of the renal pedicle 
 
Since clamping of the renal pedicle for 45 minutes led to death of the operated 
animals another series of experiments was performed in which only the renal artery 
was clamped for 45 minutes. Fig. 4.2 shows the time course of serum creatinine 
levels of clamping the renal artery alone respectively the renal pedicle. All rats, that 
underwent clamping of the renal artery recovered after a maximum increase in serum 
creatinine up to (1.4±0.4) at 24h. In contrast to rats in which the whole renal pedicle 
has been clamped for the same time, all animals recovered from ischemia 
reperfusion injury. 
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Fig. 4.2 a+b: Serum creatinine levels of rats (n=8) in which the left renal pedicle (artery and 
vein) or the artery alone has been clamped for 45 minutes. The right kidney has been 
removed before clamping.  
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5.3 45 min clamping of the renal artery vs. 60 min clamping of the renal artery 
 
To further evaluate if longer clamping of the renal artery would lead to more 
significant increase in creatinine levels, leading to a more reliable model, we 
conducted another series of experiments in which the renal artery was clamped for 
60 minutes. However the injury set by 60 minutes of warm ischemia was so severe 
that kidney function did not recover. (Fig. 4.3) 
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Fig. 4.3: Serum creatinine levels of rats (n=8) in which the left renal artery has been 
clamped for 45 or 60 minutes respectively. The right kidney has been removed before 
clamping.  
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5.4 Effects of biliverdin on kidneys after 45minutes of warm ischemia and 24h 
reperfusion 
 
Since the injury caused by clamping of the artery for 45 minutes showed to bet the 
most reproducible model in which kidney function could recover, we decided to work 
with this model to conduct our dose studies to test the effect of biliverdin and 
bilirubin-dt on ischemia reperfusion injury. Clamping of the renal artery for 45 minutes 
led to a significant increase of creatinine levels and BV treatment significantly 
decreased creatinine serum levels in a dose dependent manner. 
 
 
Fig. 4.4: Serum creatinine levels of rats (n=8) in which the left renal artery has been 
clamped for 45 minutes. The right kidney has been removed before clamping. Rats have 
been treated with biliverdin i.v. 15 minutes before clamping, 15 minutes before reperfusion, 
immediately thereafter and 10 hours after reperfusion.  
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5.5 Hematoxylin Eosin staining of kidney samples after 45min clamping of the 
renal artery 
 
After 45 minutes of warm ischemia and 24h of reperfusion, kidneys where harvested 
and formalin fixed. Hematoxylin-Eosin staining of paraffin embedded kidneys was 
performed. Picture1 shows a kidney after 45min clamping of the artery alone and 
reperfusion over 24h. Picture 2 shows a representative picture of a kidney after 
biliverdin i.v. treatment at a dose of 17.5 mg/Kg 1h before clamping and shortly 
thereafter.  (Magnification 20x). 
 
     
Fig. 4.5: Representative images of kidneys after 45 minutes of warm ischemia and 24h of 
reperfusion. The left image shows the vehicle control the right image the BV treated kidney. 
 
5.6 Effects  of  bilirubin‐ditaurine  treatment  after  kidney  transplantation  after 
18h of cold ischemia 
 
To be able to test BR-dt treatment in a more clinical relevant model we decided to 
test the potential protective effect of BR-dt on IRI in a rat kidney transplantation 
model.  
For this purpose orthotopic kidney transplantation was performed in male Lewis rats 
after 18h of cold ischemia and animals where treated with BR-dt at different doses. 
BR-dt treatment of transplanted rats resulted in a significant decrease of serum 
creatinine levels if compared to vehicle treated controls after 24 and 48h at a dose of 
10mg/Kg administered in three intravenous injections (1h before, 15min before and 
10 min after reperfusion). In addition the estimated glomerular filtration rate was 
significantly increased in the BR-dt treated group if compared to the vehicle treated 
control (Fig 4.6)  
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Fig.4.6: Serum creatinine levels after 24h of rats (n=6) in which renal transplantation was 
performed after 18h cold and 1h warm ischemia. Rats have been treated with 3 doses of 
10mg/Kg Br-dt 1h before, 15min before and 10 min after reperfusion. The right kidney has 
been removed after reperfusion. 
 
5.7 Effects  of  bilirubin‐dt  treatment  after  kidney  transplantation  after  18h  of 
cold ischemia 
 
Treatment of transplanted animals with BR-dt at a dose of 3mg/Kg respectively 
30mg/Kg did not show beneficial effects against IRI, as demonstrated in serum 
creatinine levels, if compared to the vehicle treated control. 
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Fig.4.7: Serum creatinine levels after 24h of rats (n=6) in which renal transplantation was 
performed after 18h cold and 1h warm ischemia. Rats have been treated with 3 doses of 
3mg/Kg Br-dt 1h before, 15min before and 10 min after reperfusion. The right kidney has 
been removed after reperfusion. 
 
5.8 Effects of bilirubin‐dt flush treatment after kidney transplantation after 18h 
of cold ischemia 
 
If kidneys where flushed with 125µM BR-dt prior to transplantation no beneficial 
effect on IRI could be achieved if compared to the vehicle treated control. 
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Fig. 4.8: Serum creatinine levels after 24h of rats (n=3) in which renal transplantation was 
performed after 18h cold and 1h warm ischemia. Kidneys have been flushed with 125uM BR-
dt before transplantation. The right kidney has been removed after reperfusion. 
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6. Discussion 
 
6.1. Discussion of the rationale 
 
Transplantation of solid allogeniec organs requires life long intake of 
immunosuppressive drugs to prevent the occurrence of acute rejection episodes. 
Most centres are using immunosuppressive protocols in which a combination of 
calcineurin inhibitors and antiproliferative agents are successful combined with an 
induction therapy (e.g. anti-thymocyte globulin, IL2-antagonists). The potent 
immunosuppressive effect of those drugs leads however to severe side effects as a 
higher incidence of tumours and viral, fungal and bacterial infections.  
Unfortunately the introduction of more potent immunosuppressive agents has not let 
to the expected improvement of long term outcome after solid organ transplantation. 
(Fig. 1.7). 
 
Ischemia reperfusion injury occurs during the re-establishment of blood flow in the 
transplanted organ leading to an abrupt delivery of O2. Since the graft was exposed 
to ischemia during the time of transplantation, the mitochondrial electron transport 
chain cannot instantly use O2, leading to an accumulation of O2, which is now 
available for oxidative enzymes, consequently leading to the formation of reactive 
oxygen species (ROS). These ROS can lead to DNA damage, oxidative modification 
of proteins and lipid peroxidation, which show cytotoxic effects. 
The severity of ischemia reperfusion is held responsible for delayed graft function 
(DGF) of the transplanted organ as well as the long-term outcome after kidney 
transplantation.  
Aim of our study was to investigate the potential protective effects of BR in a rodent 
model of kidney transplantation. 
 
6.2. Discussion of the model and methods 
 
In our experimental setup we decided to work with two different animal models of 
ischemia reperfusion injury. The kidney clamp model was chosen because of its easy 
technical feasibility and its high reproductivity. With this model a dose study was 
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performed in order to find the right protective dose regimen to be tested in the clinical 
more relevant kidney transplantation model.  
6.2.1 Warm ischemia reperfusion model of the rat: 
 
In the first experimental setting clamping of the whole renal pedicle was performed. 
This experimental setting however led to a severe damage of the kidney and animals 
didn’t recover from surgery after 76h due to acute renal failure.  
If however only clamping of the renal artery was performed, the increase in serum 
creatinine levels was not as severe and animals could recover from surgery. We 
think that the higher damage in the pedicle group can be explained by the 
occurrence of thrombosis in the clamped kidney, since venous outflow was clamped 
during the 45 minutes of warm ischemia.  
If clamping of the renal pedicle was performed the kidney showed a dark blue colour 
after 45minutes of warm ischemia and the reperfusion period took much longer if 
compared to the artery alone group.  
For this reason we decided to work with the ischemia reperfusion injury model of the 
rat, in which only the artery is clamped.  
In our clamping data, 3 administrations of biliverdin in a dose of 10mg/Kg led to 
significant decrease of serum creatinine levels after 45 minutes of warm ischemia 
and 24h of reperfusion. 
Encouraged by these findings we decided to work with this dose regimen to test the 
potential beneficial effects of bilirubin on ischemia reperfusion injury in a more clinical 
relevant model of kidney transplantation in the rat. 
 
6.2.2 Kidney Transplantation Model: 
 
Kidney transplantation is a well-established model in transplantation research and 
experimental microsurgery (73,74). 
Fisher and Lee first described the heterotopic rat kidney transplantation model in 
1965 (75) and the orthotopic technique was published in 1968 by Daniller et al. (76). 
 
Kidneys were explanted 18h prior to transplantation and preserved in 4°C cold UW-
solution. After this period of 18h cold ischemia kidneys were transplanted 
orthotopically into the recipient rat and the warm ischemic time was kept constantly 
at 60 minutes. Serum concentrations of creatinine and BUN were taken at different 
time points. 
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Serum creatinine levels, serum BUN levels were significantly decreased if compared 
to the untreated control if animals were treated with 3 injections of 10mg/kg Biliruibn-
dt.  
Lower (3x3mg/Kg) or higher (3x20mg/Kg) doses of Bilirubin-dt administration could 
not achieve protection against the caused ischemia reperfusion injury.  
Encouraged by earlier findings in our laboratory that bilirubin rinse of transplanted 
hearts showed beneficial effects against ischemia reperfusion injury (unpublished 
data) we tested this treatment regimen in our kidney transplantation model. As 
demonstrated in Fig. 4.8 bilirubin-dt rinse of the transplanted kidney prior to 
transplantation at a dose of 125µM did not protect the organ from ischemia 
reperfusion injury. 
 
6.3 Bilirubin and HO‐1: 
 
The heme oxygenase system is the rate-limiting step in the conversion of heme into 
free iron, carbon monoxide and biliverdin.  
HO-1 is activated by cellular stress such as inflammation, ischemia, radiation or 
hypoxia (68) and is known to play a crucial role in maintaining oxidant/antioxidant 
homeostasis during cell injury (69). 
In 1987, Stocker et al. was the first to introduce the idea that BR is one of the most 
important endogenous antioxidant in the serum (70). In subsequent conducted 
studies it could be demonstrated that induction of HO-1 leads to BR-mediated 
reduction of oxidative stress in animal models of renal ischemia (71) and cardiac 
ischemia (72). 
 
Fig. 4.9: Effects of bilirubin and biliverdin in animal models of IRI  
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The chemical induction of HO-1 to improve kidney function after ischemia reperfusion 
injury has been the target of many ongoing and already published data. Those could 
demonstrate that pharmacological induction of HO-1 led to a better functional and 
structural outcome after ischemia reperfusion injury to the kidney. In contrast 
inhibition of HO-1 led to more severe injury after reperfusion (77). 
The protective actions of HO-1 induction during ischemia reperfusion injury are 
realized via its downstream products CO, Biliverdin and Free iron. Those molecules 
effectuate their beneficial actions through inhibiton of apotosis, the scavenging of 
free radicals and the maintenance of medullary blood flow. Moreover leukocyte 
recruitment and platelet aggregation are inhibited (Fig 5.0). 
 
 
 
Fig. 5.0: Putative actions of HO-1 during ischemia reperfusion injury. (78) 
 
6.4. Exogenous administration of Bilirubin leads to improved graft function after 
18h of cold ischemia . 
 
Aim of our study was to examine if exogenous administered Biliverdin/Bilirubin led to 
similar protective effects on transplanted kidneys that have been exposed to 
ischemia reperfusion injury. 
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Kirkby et al. tested the effect of intravenous administered bilirubin on ischemia 
reperfusion injury in the rat. His group clamped both renal pedicles for 30min and 
analyzed the potential protective effect of bilirubin administration after 6h of 
reperfusion. They could not observe a beneficial effect if bilirubin was administered at 
a dose of 5mg/Kg respectively 20mg/Kg 1h before and during ischemia (51). One 
explanation for these negative results could be the tested model. As mentioned 
above, clamping of the renal pedicle for 45minutes led to a severe injury of the tested 
kidney and the animals did not recover from surgery, suggesting, that the caused 
damage was to severe.  
In our model of warm ischemia reperfuison injury, if only the artery alone was 
clamped, exogenous bilirubin administration via i.p. injection led to significant 
decrease in serum creatinine levels after 24h of reperfusion showing an intact cell 
integrity of the treated kidney if compared to the control group. (Fig 4.4, Fig 4.5). 
 
 
In summary we could show that exogenous, systemic administration of bilirubin-dt 
could achieve an improved kidney function after 18h of cold ischemia and isogenic 
kidney transplantation. 
One explanation for the observed protective effect of bilirubin administration could be 
its potent antioxidant effect. However more research needs to be conducted to 
understand and explain the underlying mechanism by which bilirubin exerts its 
protective effects.  
Moreover, bilirubin needs to be tested in an allogenic kidney transplantation model in 
order to test the potential protective effects of bilirubin in a more clinical relevant 
model. 
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7. Abstract: 
 
Background: 
 
Heme oxygenase-1 (HO-1) is the rate-limiting enzyme in the conversion of heme into 
biliverdin, carbon monoxide (CO) and free iron. Biliverdin is then subsequently 
reduced to bilirubin by the enzyme bilverdin reductase. In the past decades a lot of 
effort was conducted to investigate the beneficial effects of HO-1 and its end 
products biliverdin/bilirubin and CO. 
 
Due to intensive research, solid organ transplantation can nowadays be seen as 
clinical routine. However ischemia reperfusion injury (IR), acute rejection episodes 
and the occurrence of chronic rejection remain main problems.  
The severity of IRI can be seen as a prognostic factor for early graft function, 
immunogenecity of grafts as well as for long term graft survival. 
The goal of our experiments was to investigate the potential beneficial effects of 
bilirubin and biliverdin on ischemia reperfusion in a kidney transplantation model of 
the rat. 
 
Methods: 
 
Two different sets of experiments were performed: 
First, kidneys of Lewis rats were exposed to 60 minutes of warm ischemia by 
clamping the renal artery followed by a 24h reperfusion period. This model was used 
to find the optimal dosing regimen of bilirubin/biliverdin before the more clinical 
relevant model of kidney transplantation in the rat was performed. We found that 
three doses of 10mg/Kg bilirubin were the most effective dose regimen to protect 
kidneys from ischemia reperfusion injury.  
In the second set of experiments, kidney transplantation was performed in Lewis 
rats. Kidneys were harvested and stored in 4°C cold UW-solution for 18h. 
Subsequently the kidneys were transplanted isotopically into the recipient rat. Time 
of warm ischemia was kept in all experiments constantly at 60 minutes. After 24h of 
reperfusion tissue samples and serum were harvested for further analyses.  
 
    Abstract 
Dr.med.univ Michael Thomas 45 
Results: 
 
Systemic treatment of bilirubin led to a significant amelioration of organ function after 
ischemia reperfusion injury as assessed by measuring serum creatinine levels and 
BUN levels after 24h of reperfusion. In addition treated animals showed increased 
eGFR and a better cell integrity as histomorphological analyses could demonstrate. 
 
Conclusion: 
 
Systemic treatment with bilirubin and bilverdin has beneficial effects on graft function 
after ischemia rerperfusion injury.  
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Hintergrund: 
 
Heme oxygenase-1 (HO-1) ist das geschwindigkeits- bestimmende Enzym bei der 
Umwandlung von Häme zu Biliverdin, Kohlenmonoxid und freiem Eisen. Biliverdin 
wird dann in einem folgendem Schritt durch das Enzym Biliverdin-Reduktase in 
Bilirubin umgewandelt. In den letzten Jahrzehnten wurde intensive Forschung 
betrieben um die protekitven Eigenschaften von HO-1 und seiner Endprodukte 
Biliverdin/Bilirubin und Kohlenmonoxid zu untersuchen. 
 
In der heutigen Zeit kann man die Transplantation von soliden Organen dank großer 
Forstschritte auf dem Gebiet der Immunsupression und durch die Verbesserung 
chirurgischer Techniken als klinische Routine ansehen. Trotzdem bleiben weiterhin 
große Probleme bestehen, wie akute Abstoßungsreaktionen sowie das Auftreten der 
chronischen Abstoßung und des Ischämie Reperfusionsschadens.  
Die Schwere des Ischämie Reperfusionsschadens dient als prognostischer Faktor für 
die frühzeitige Organfunktion als auch für das Langzeitüberleben des Transplantats. 
Ziel dieser Arbeit war es, den potentiell protektiven Effekt von Bilirubin und Biliverdin 
in einem Ischämie-Reperfusionsmodell zu testen. 
 
 
Methoden: 
 
Nieren von Lewis Ratten wurden 60 Minuten warmer Ischämie ausgesetzt, indem die 
Nierenarterie geklemmt wurde. Dieses Modell diente der Erforschung der optimalen 
Dosis von Bilirubin und Biliverdin bevor das aufwendigere und klinisch relevantere 
Modell der Nieren Transplantation in der Ratte durchgeführt wurde. Eine Dosis von 
insgesamt 30mg/Kg administriert in 3 Einzeldosen a 10mg/Kg stellte sich als die 
effektivste Therapie dar. 
Für das Nierentransplantationsmodel wurden Nieren von Lewis Ratten explantiert 
und für 18h in 4°C kalter UW-Lösung präserviert. Hiernach wurden die Nieren in 
unten beschriebener Technik in die Empfängerratte transplantiert. Nach 24h 
Reperfusion wurden Gewebeproben sowie Serum für die Durchführung weiterer 
Untersuchungen entnommen. 
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Resultate: 
 
Die systemische Behandlung mit Bilirubin führte zu einer signifikanten Besserung der 
Organfunktion nach Ischämie Reperfusion wie wir durch die Bestimmung der 
Serumkreatinin- und Serumharnstoff-Werte demonstrieren konnten. Außerdem führte 
die Behandlung mit Bilirubin zu einer signifikant gesteigerten eGFR sowie einer 
Erhaltenen Zellintegrität, wie histologisch gezeigt werden konnte. 
 
Schlussfolgerung: 
 
Systemische Behandlung mit Bilirubin und Bilivedin zeigt protektive Effekte auf die 
Organfunktion nach Ischämie-Reperfusionsschaden. 
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